TERMINATED

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.

Official Title

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Quick Facts

Study Start:2025-02-25
Study Completion:2025-07-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:TERMINATED

Study ID

NCT06673368

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:13 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Guy Bar-Klein, PhD
STUDY_DIRECTOR
Neurocentria, Inc.

Study Locations (Sites)

Accel Research Site-Maitland Clinical Research Unit
Maitland, Florida, 32751
United States
iResearch Atlanta
Decatur, Georgia, 30030
United States
CenExel iRS - iResearch Savannah
Savannah, Georgia, 31405
United States
Boston Clinical Trials LLC
Boston, Massachusetts, 02131
United States
Center For Psychiatry and Behavioral Medicine
Las Vegas, Nevada, 89128
United States

Collaborators and Investigators

Sponsor: Neurocentria, Inc.

  • Guy Bar-Klein, PhD, STUDY_DIRECTOR, Neurocentria, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-25
Study Completion Date2025-07-15

Study Record Updates

Study Start Date2025-02-25
Study Completion Date2025-07-15

Terms related to this study

Additional Relevant MeSH Terms

  • ADHD